Securities Class Action Filed Against Atara Biotherapeutics: Investors Urged to Contact Kirby McInerney LLP for Lead Plaintiff Appointment

A class-action lawsuit has been filed against Atara Biotherapeutics, Inc. for allegedly overstating the regulatory prospects of its tabelecleucel BLA and manufacturing issues that jeopardized ongoing clinical trials. The lawsuit claims that investors suffered losses after the FDA issued two Complete Response Letters and placed a clinical hold on the company's active IND applications.